Correlation Of 12-Weeks Decrease Of Ca19.9 With Overall Response Rate (Orr) And Progression Free Survival (Pfs) In Advanced Pancreatic Cancer (Apc) Patients (Pts) Treated With First-Line Nab-Paclitaxel (Nab-P) And Gemcitabine (G)

e15256 Background: Nab-P and G have shown superiority both in terms of activity and efficacy versus G alone as a first line treatment for APC in a phase III randomised trial. In the same trial CA 19.9 response has been related to a longer Overall Survival (OS). Here we report data on our experience about the correlation between CA 19.9 response, ORR and PFS in a single cohort of pts receiving first line Nab-P + G for APC. Methods: 34 pts receiving combination of nab-P 125 mg/m2 + G 1000 mg/m2 days 1, 8, and 15 every 4 weeks were included in our analysis. CA19.9 was evaluated at baseline and then every 12 weeks. ORR defined as Complete Responses (CR) + Partial Responses (PR) was detected by PET-CT scan every 12-weeks according to RECIST v1.0 criteria. Pearson correlation analysis was performed to evaluate relation between CA19.9 response, ORR and PFS. Results: The median age was 67 years (range 37 - 77) and ECOG PS was 0 (11.7%), 1 (70.6%), 2 (17.7%). Pts had advanced disease with liver metastases (58.8%),...